Quang X. Pham, serving in the dual capacities of Chairman and Chief Executive Officer at Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), has executed a transaction involving the disposition of company equity. Additionally holding the title of Interim Chief Financial Officer, Mr. Pham sold shares of the company's common stock with a total transaction value of $13,110. The execution of these sales was not a singular event but occurred across a two-day period, with share prices fluctuating between $3.16 and $3.18 per share during the process.
Regulatory filings submitted to the Securities and Exchange Commission provide the specific chronology of these divestments. On June 16, 2026, Mr. Pham disposed of 3,613 shares. The following day, June 17, 2026, he sold an additional 513 shares. The structure of these transactions was governed by a Rule 10b5-1 trading arrangement. Mr. Pham originally adopted this pre-arranged plan on September 25, 2025, a timeframe that precedes the execution of the sales by several months. The utilization of this specific regulatory framework indicates that the timing of the sales was dictated by the parameters of the plan rather than market timing decisions made at the point of sale.
The insider transaction occurs against a backdrop of significant price depreciation for Cadrenal Therapeutics. Over the trailing twelve-month period, the company's shares have declined by 74%. As of the reporting date, the stock was trading at $3.50, a figure that stands in stark contrast to its 52-week high of $14.64. Technical analysis provided by InvestingPro, which covers a broad spectrum of United States equities, indicates that the stock currently resides in oversold territory based on Relative Strength Index (RSI) indicators. However, the analysis also notes that volatility within the security remains elevated, suggesting continued price instability despite the oversold classification.
Following the completion of these recent sales, Mr. Pham's direct ownership stake in Cadrenal Therapeutics has been adjusted. He now holds a direct position of 128,589 shares of the company's common stock. Beyond his direct holdings, Mr. Pham maintains an indirect stake through The PVBQ Living Trust. He serves as the Trustee of this entity, holding sole voting and dispositive power over the assets. The trust holds 200,000 shares of Cadrenal Therapeutics. Mr. Pham's child is identified as the sole beneficiary of this trust structure. In addition to his executive roles, Mr. Pham is formally recognized as a Director and a Ten Percent Owner of the company.
Concurrent with the insider activity, Cadrenal Therapeutics has reported financial results for the fourth quarter ending December 31, 2025. The company recorded a net loss of $3.0 million for this period. While the company remains unprofitable, this figure represents an improvement compared to the $4.2 million net loss reported during the same period in 2024. The reduction in the quarterly loss suggests a potential stabilization in the company's burn rate or operational efficiency, although the absolute loss remains substantial.
On the clinical development front, Cadrenal has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The discussion centered on the company's planned Phase 3 trial for CAD-1005, an investigational treatment targeting heparin-induced thrombocytopenia. During the meeting, the FDA provided guidance on multiple critical aspects of the trial design, including the protocol structure and the requirements for the safety database. Based on this regulatory feedback, Cadrenal plans to initiate a randomized, blinded, placebo-controlled Phase 3 study. The trial is designed to enroll approximately 120 patients on a global scale. This progression marks a significant milestone in the regulatory pathway for the drug candidate.
Furthermore, the company has announced strategic initiatives regarding its pipeline expansion. Cadrenal plans to submit a request for Rare Pediatric Disease Designation for tecarfarin. This designation would apply to the use of tecarfarin as a treatment for pediatric patients suffering from Kawasaki disease. The strategic objective of this designation is to address coronary artery aneurysms in children who require chronic oral anticoagulation. These developments highlight the company's ongoing efforts to advance its portfolio of investigational therapies and diversify its therapeutic targets beyond the primary indication for CAD-1005.